FIL_MIMYC
Multicenter, Observational, Retrospective-prospective Study Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
Sponsor study identifier
observational
200
1 country
20
Study Start
May 5, 2025
Actual (reported)Primary Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a observational, retrospective and prospective study designed to assess the potential correlations between MYC alterations, lymphoma mutational landscape and functional immune contextures in Diffuse Large B-cell Lymphoma or High-Grade B-cell Lymphoma
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2, 2024
Actual (reported)September 19, 2024
Actual (reported)May 5, 2025
Actual (reported)December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Evaluate the histopathological, genetic, clinical characteristics and outcome of patients with DLBCL or HGBCL with MYC rearrangements or GCN (alone or in association with BCL2 and BCL6) treated with curative intent therapy
Comparison of Progression Free Survival (PFS) according to genetic subgroups with or without intensified treatment
The endpoint will be evaluated from the beginning to the end of the study (up to 36 months)
Identify biological relationship between MYC aberration, gene mutations and patterns of immune microenvironment in B-cell lymphomas with DLBCL or high-grade morphology
The endpoint will be evaluated from the beginning to the end of the study (up to 36 months)
Identify biological relationship between MYC aberration, gene mutations and patterns of immune microenvironment in B-cell lymphomas with DLBCL or high-grade morphology
Patient affected by DLBCL or HGBL with MYC alterations treated with standard R-chemotherapy regimens as first line treatment
Patient affected by DLBCL or HGBL with MYC alterations treated with standard R-chemotherapy regimens as first line treatment
A.O.U. SS. Antonio e Biagio e C. Arrigo - S.C.D.U. Ematologia
Alessandria, Italy
A.O.U. Ospedali Riuniti delle Marche - Clinica di Ematologia
Ancona, Italy
Luisa Lorenzi, MD
SC Anatomia Patologica - ASST Spedali Civili di Brescia
First Submitted
September 2, 2024
First Posted
September 19, 2024
Study Start
May 5, 2025
Actual (reported)Primary Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
The endpoint will be evaluated from the beginning to the end of the study (up to 36 months)
Identify biological relationship between MYC aberration, gene mutations and patterns of immune microenvironment in B-cell lymphomas with DLBCL or high-grade morphology
The endpoint will be evaluated from the beginning to the end of the study (up to 36 months)
Identify putative prognostic and predictive biomarkers related to the lymphoma microenvironment
The endpoint will be evaluated from the beginning to the end of the study (up to 36 months)
Analyze the impact of the type of therapy, standard or intensified (with or without autotransplantation), on the outcome in the different subgroups of patients
The endpoint will be evaluated from the beginning to the end of the study (up to 36 months)
Contact the study team to confirm eligibility.
I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia
Bari, Italy
ASST Spedali Civili - S.C. Ematologia
Brescia, Italy
I.R.C.C.S. Istituto di Candiolo - FPO
Candiolo, Italy
I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncoematologia
Castelfranco Veneto, Italy
ARNAS Garibaldi - U.O.C. Ematologia
Catania, Italy
A.S.T. Macerata - U.O.S.D Ematologia
Civitanova Marche, Italy
Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia
Florence, Italy
ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia
Milan, Italy
Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda - S.C. Ematologia
Milan, Italy
A.O.U. di Padova - U.O.C. Ematologia
Padova, Italy
I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncologia 1
Padova, Italy
AUSL Modena sede di Sassuolo - UOSD di Oncologia Area Sud
Sassuolo, Italy
U.O.C. Ematologia - A.O.U. Senese
Siena, Italy
A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U
Torino, Italy
ULSS 2 Ospedale Ca' Foncello - U.O.C. Ematologia
Treviso, Italy
A.O. Cardinale "G. Panico" - U.O.C Ematologia e Trapianto Midollo Osseo
Tricase, Italy
A.S.U. Giuliano Isontina - S.C. Ematologia
Trieste, Italy
A.O.U.I. di Verona - Ematologia
Verona, Italy
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
December 29, 2025
Record last verified: 2025-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: